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location, antimicrobial exposure was associated with a higher risk of CA-CDI in the
USA, whereas proton pump inhibitor exposure was associated with a higher risk in
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Europe. By life stages, the risk of CA-CDI associated with antimicrobial exposure
greatly increased in adults aged >65 years.
Conclusions: Antimicrobial exposure was the strongest risk factor associated with CA-
CDI. Further studies are required to investigate the risk of CA-CDI associated with
medications commonly prescribed in the community and patients with diarrhoea who
have inflammatory bowel disease, renal failure, haematological cancer, or diabetes
mellitus seem to be the appropriate populations for interventional studies of screening.
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ABSTRACT 1 
Background: Clostridium difficile infection (CDI) has been extensively described in health-2 
care settings; however, risk factors associated with community-acquired (CA)-CDI remain 3 
uncertain. Therefore, this study aimed to synthesise the current evidence for an association 4 
between commonly prescribed medications and comorbidities with CA-CDI. 5 
 6 
Methods: A systematic search was conducted in five electronic databases for 7 
epidemiological studies that examined the association between the presence of comorbidities 8 
and exposure to medications with the risk of CA-CDI. Pooled odds ratios were estimated 9 
using three meta-analytic methods. Subgroup analyses by the location of the studies and by 10 
life stages were conducted.  11 
 12 
Results: Twelve publications (n=56,776 patients) met the inclusion criteria. Antimicrobial 13 
(OR:6.18; 95%CI:3.80-10.04) and corticosteroid (OR:1.81; 95%CI:1.15-2.84) exposure were 14 
associated with an increased risk of CA-CDI. Among the comorbidities, inflammatory bowel 15 
disease (OR:3.72; 95%CI:1.52-9.12), renal failure (OR:2.64; 95%CI:1.23-5.68), 16 
haematological cancer (OR:1.75; 95%CI: 1.02-5.68) and diabetes mellitus (OR:1.15; 17 
95%CI:1.05-1.27) were associated with CA-CDI. By location, antimicrobial exposure was 18 
associated with a higher risk of CA-CDI in the USA, whereas proton pump inhibitor 19 
exposure was associated with a higher risk in Europe. By life stages, the risk of CA-CDI 20 
associated with antimicrobial exposure greatly increased in adults aged >65 years. 21 
 22 
Conclusions: Antimicrobial exposure was the strongest risk factor associated with CA-CDI. 23 
Further studies are required to investigate the risk of CA-CDI associated with medications 24 
commonly prescribed in the community and patients with diarrhoea who have inflammatory 25 
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bowel disease, renal failure, haematological cancer, or diabetes mellitus seem to be the 1 
appropriate populations for interventional studies of screening.  2 
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INTRODUCTION 1 
 While the previous literature has focused largely on healthcare-associated (HA) 2 
Clostridium difficile infection (CDI); the incidence, prevalence and severity of community-3 
acquired (CA)-CDI has also increased.
2
 Kuntz et al.
9
 reported similar incidence rates for CA-4 
CDI (11.2 cases/100,000 person-years) and HA-CDI (12.1 cases/100,000 person-years) in the 5 
USA. Moreover, the emergence of “hypervirulent” strains of C. difficile in the community 6 
among patients previously considered to be at low risk of CDI (i.e. young adults without 7 
antimicrobial exposure) clearly shows that the epidemiology of CDI is changing and that CDI 8 
is no longer exclusively a nosocomial infection as it was previously considered.
2
 It seems that 9 
the risk profile of patients from the community points more to increased numbers of younger 10 
patients without comorbidities, whereas, in the hospital setting, elderly inpatients with 11 
multiple morbidities and exposed to polypharmacy remain most at risk.  12 
Research, including through meta-analysis, has attempted to describe the risk of CDI 13 
specifically in the community setting and found that clindamycin, fluoroquinolones, 14 
cephalosporins, macrolides, penicillins and sulphonamides/trimethoprim are associated with 15 
an increased CA-CDI risk.
10,11
 The evidence however remains uncertain as these meta-16 
analyses used the random-effects (RE) model which has been questioned for its overconfident 17 
results.
12
 Exposure to gastric-acid suppressive drugs
3-5,13-15
 and the presence of 18 
comorbidities
6-8
 are associated with an increased risk of HA-CDI; but as with antimicrobials, 19 
the evidence remains inconclusive in the community setting. Therefore, the current meta-20 
analysis was undertaken to pool the evidence from observational studies so that the 21 
magnitude and direction of the association between commonly prescribed medications and 22 
comorbidities with CA-CDI can be documented.   23 
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METHODS 1 
Search methodology 2 
 A systematic search was undertaken in five medical and life sciences databases 3 
(PubMed, Embase, Cochrane CENTRAL, CINAHL and Scopus) from their inception to 4 
March 1
st
 2014 (Appendix 1). A related citation search was also performed; by combining the 5 
systematic search with the first 20 studies from the related citation search of selected articles 6 
in PubMed, a comprehensive evaluation of the published evidence can be achieved.
16
  7 
 8 
Eligibility criteria 9 
 The inclusion of studies was restricted to human studies, full-text articles written in 10 
English, studies reporting CA-CDI, and data presented in an extractable format. Conference 11 
presentations and abstracts, studies that exclusively compared CA-CDI with HA-CDI, and 12 
studies that presented data in a non-extractable format (i.e. graphical representations) were 13 
excluded. Exclusions were also made for studies that investigated specific groups (i.e. 14 
patients with HIV or cirrhosis) as these were not considered representative of the general 15 
population. 16 
 17 
Study selection and data extraction 18 
 Two authors (LFK and JCS) independently evaluated all the citations by titles and 19 
abstracts for studies that met the eligibility criteria. Full-text version articles of all potentially 20 
relevant studies were retrieved and independently assessed for eligibility. Data from the 21 
included studies were then independently extracted using a predefined tool (Appendix 2) and 22 
summarized in a spreadsheet by the same two authors. Extracted data were cross-checked by 23 
the two authors, discrepancies during the selection of studies or data extraction were resolved 24 
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through discussion and consensus following independent evaluation by another author 1 
(SARD).   2 
 3 
Quality assessment 4 
 The quality of each study was assessed using a modified version of the Newcastle-5 
Ottawa quality assessment scale for case-control studies. The modified scale assessed 6 
whether seven safe-guards against bias had been undertaken by the authors (i)definition of 7 
cases and methods employed for C. difficile diagnosis, (ii) selection of CA infection, 8 
(iii)control definition and the method used to rule out C. difficile, (iv) selection of controls 9 
from the community, (v)analysis adjusted for confounders, (vi)method used for ascertainment 10 
of exposure, (vii)same method used to ascertain exposure for cases and controls. The quality 11 
criteria were combined into a univariate score as outlined in Table 2. The quality score was 12 
rescaled between zero and 1 (called Qi); this was done by summing the points of each 13 
component (maximum sum = 17) and dividing it by the highest sum obtained by a study 14 
within the meta-analysis, ensuring that the best quality study always had a Qi of 1. 15 
 16 
Statistical analyses 17 
 The outcome measure was the odds ratio (OR) for the association of CA-CDI with 18 
exposure to risk factors such as antimicrobial drugs, gastric acid suppressant drugs (proton-19 
pump inhibitors [PPI] and histamine-2-receptor antagonists [H2RAs]), non-steroidal anti-20 
inflammatory drugs (NSAIDs), aspirin, steroids and the presence of comorbidities. The OR 21 
was pooled using three meta-analytic models. This was justified because some have 22 
expressed skepticism regarding the appropriateness of the conventional RE model
17
 due to its 23 
documented underestimation of the statistical error, which leads to overconfident results.
12,18-24 
20
 The other two models that were used were the quality-effects (QE) model,
21,22
 and a novel 25 
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method, the inverse variance heterogeneity (IVhet) model.
23
 The QE model uses the Qi to 1 
redistribute the inverse variance weights in favor of the studies with higher methodological 2 
quality and thus studies that provided higher quality of evidence contributed with a higher 3 
weighting towards the overall effect size.
22
 This use of quality information via a univariate 4 
score does not imply that quality deficiencies can quantify bias. Rather, the quality score is 5 
used to rank studies by methodological rigor and this rank is then linked with a synthetic bias 6 
variance that is added to the random error variance.
21
 The other model used was the IVhet 7 
model that does not require input of quality information so is less rigorous than the QE 8 
model.
23
 Both of the latter models use a quasi-likelihood based variance structure without 9 
distributional assumptions and thus have coverage probabilities for the confidence interval 10 
(CI) well above the nominal level.
23 The reported results are based on the IVhet model; 11 
results using the QE and RE models have been presented for comparative purposes. 12 
Statistically significant heterogeneity was defined as tau-squared statistic ( 2 ) >0, 13 
Cochran's Q test p-value <0.1 or 2I index >0%. A sensitivity analysis was conducted to 14 
determine the degree to which the findings vary depending on the geographical location 15 
where the studies were conducted (America or Europe) and life stages of the participants 16 
(children aged <2 years, children and adults, adults or adults aged >65 years).  17 
 The Doi plots were used to evaluate the presence of publication bias, which plots the 18 
lnOR against the absolute value of the z-score for each study.
24
 Funnel plots were not 19 
reported as the graphical assessment of publication bias requires at least 10 studies and even 20 
then can be difficult to interpret.
25
 21 
 The results of the analyses were considered statistically significant if the 95%CI did 22 
not include zero. Analyses were conducted using MetaXL version 2.0 (EpiGear Int Pty Ltd; 23 
Brisbane; Australia; www.epigear.com).  24 
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RESULTS 1 
Yield of search strategy 2 
 The initial search identified 1,663 publications. An additional 124 publications were 3 
retrieved throughout the related citations search. After excluding duplicate citation 1,481 4 
publications remained. After screening the publications by title and abstract, 1,388 were 5 
excluded. Full-text review of 93 publications was conducted, 12 met the eligibility criteria 6 
and were selected for the meta-analysis (Figure 1).  7 
 There was overlap in subjects between 2 sets of publications. Two publications (Dial 8 
et al., 2005
26
 and Delaney et al., 2007
27
) used data from the UK General Practice Research 9 
Database (GPRD) between 1994-2004 and a positive toxin test result for CDI as case 10 
definition to assess the risk of CA-CDI with antimicrobial exposure. Although, Dial et al., 11 
2006
28
 also used data from the UK GPRD, the authors reported that there was no overlap 12 
between this and Dial et al., 2005
26
 as they used different case definitions for CDI.
28
 13 
Additionally, two publications (Soes et al., 2013a
29
 and Soes et al., 2013b
30
) reported results 14 
from the same Danish cohort. Therefore, Delaney et al., 2007
27
 and Soes et al., 2013b
30
 were 15 
excluded from the analyses. 16 
 17 
Characteristics of the included studies 18 
  Twelve publications were included in the meta-analysis. Two publications reported 19 
results divided into groups. Kutty et al.
31
 presented the results of two populations (Veterans 20 
Affairs and Durham County residents), whereas Soes et al.
29,30
 presented the results divided 21 
into two age groups (<2 years and ≥2 years). Among the included studies, seven were case-22 
control studies and five were nested case-control studies. The studies included covered more 23 
than 35 years of research and 56,776 patients in 6 different countries. The age of the 24 
participants ranged between 3 months and 101 years. Only one study
29,30
 used exclusively 25 
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positive C. difficile culture in the case definition and another study
32
 used a combination of C. 1 
difficile culture or toxin test results in the case definition. All studies evaluated exposure to 2 
medication and presence of comorbidities for at least 6 and 12 weeks prior to the index date, 3 
respectively (Table 1). The quality score of the studies ranged from 9 to 13 out of 17 (Table 4 
2). 5 
 6 
Quantitative synthesis 7 
 When examining the association between drug exposures and CA-CDI using the 8 
IVhet model, exposure to antimicrobials (OR:6.18; 95%CI: 3.80-10.04) and corticosteroids 9 
(OR:1.81; 95%CI: 1.15-2.84) were significantly associated with CA-CDI. Gastric acid-10 
suppressing drugs (PPIs and H2RAs; OR:1.58; 95%CI: 0.90-2.75), PPIs (OR:1.61; 95%CI: 11 
0.90-2.88) and H2RAs (OR:1.24; 95%CI: 0.76-2.01) were not associated with increased odds 12 
of CA-CDI. Statistically significant associations were found between CA-CDI and the 13 
presence of inflammatory bowel disease (IBD; OR:3.72; 95%CI: 1.52-9.12), renal failure 14 
(OR:2.64; 95%CI: 1.23-5.68), leukemia or lymphoma (OR:1.75; 95%CI 1.02-3.03) and 15 
diabetes mellitus (OR:1.15; 95%CI: 1.05-1.27; Table 3). 16 
 Visual inspection of the forest plots, Cochran's Q test (Appendix 3), 2  (results not 17 
shown) and 2I index (Table 3 and Appendix 3) confirmed heterogeneity across studies, 18 
except for exposure to tetracyclines or aspirin and the presence of chronic obstructive 19 
pulmonary disease (COPD), diabetes mellitus or diverticular disease.  20 
 21 
Sensitivity analysis 22 
 A sensitivity analysis was only possible for antimicrobial and PPI exposure because 23 
of the small number of studies in the other categories. When stratifying the studies by 24 
geographic location, the sensitivity analysis showed that antimicrobial exposure had a greater 25 
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association with CA-CDI in the USA (OR:9.16; 95%CI: 5.47-15.34) compared to European 1 
countries (OR:4.54; 95%CI: 2.68-7.70; Appendix 4.1). Conversely, exposure to PPIs had a 2 
stronger association with CA-CDI in Europe (OR:2.56; 95%CI: 1.40-4.71) compared to the 3 
USA (OR:1.12; 95%CI: 0.64-1.95; Appendix 4.2).  4 
 The subgroup analysis by life stages showed that older adults (>65 years) had the 5 
highest risk (OR:10.16; 95%CI: 5.56-18.58) of CA-CDI when exposed to antimicrobials 6 
followed by children and adults (OR:5.98; 95%CI: 4.67-7.67; Appendix 4.3). When exposed 7 
to PPIs, adults had the highest risk of CA-CDI (OR:2.78; 95%CI: 2.02-3.81; Appendix 4.4). 8 
 9 
Publication bias 10 
 On visual inspection of the Doi plots, there was gross asymmetry for some exposures 11 
suggesting publications bias in relation to cephalosporins, fluoroquinolones, macrolides, 12 
penicillin, presence of congestive heart failure and gastro-esophageal reflux disease. The bias 13 
was towards selective publication that reported medication exposure and presence of 14 
comorbidities as risk factors for CA-CDI (Appendix 3).   15 
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DISCUSSION 1 
 Exposure to antimicrobials remained the strongest risk factor associated with CA-2 
CDI. No statistical significance was observed in the majority of the analyses by antimicrobial 3 
class, likely due to the largest study (Lowe et al.
33
) reporting ORs close to the null value. 4 
However, point estimates confirmed a trend towards an association with CA-CDI regardless 5 
of antimicrobial class exposure. These observations corroborated previous findings published 6 
by Deshpande et al.
10
 and Brown et al.
11
 which suggested an increased risk of CA-CDI as a 7 
result of antimicrobial exposure. 8 
 Despite the increasing evidence in the past decade with respect to increased risk of 9 
HA-CDI after exposure to PPIs
3,4,13-15
 or H2RAs,
5,26
 no significant association was observed 10 
in the community setting. The observed difference between the risk of CA-CDI and HA-CDI 11 
with gastric-acid suppressive medication can be explained by the overutilization of these 12 
medications in healthcare facilities.
34
 Exposure to corticosteroids was associated with CA-13 
CDI. In contrast to antimicrobials which disrupt the normal gut microbiome facilitating the 14 
proliferation of C. difficile,
35
 and gastric-acid suppressive medication that may allow survival 15 
of vegetative forms of C. difficile,
36
 a plausible biological mechanism for the observed 16 
association could be the negative impact of corticosteroids on the gastrointestinal mucosal 17 
integrity.
37
  18 
 Previous studies found that gastrointestinal comorbidities such as IBD
6
 and cirrhosis
8
 19 
were associated with a worse prognosis in patients with CDI. Similarly, congestive heart 20 
disease, chronic pulmonary disease, renal failure and malignancies were also associated with 21 
higher mortality rates among inpatients with CDI.
7
 Among the comorbidities examined in 22 
this meta-analysis, IBD was the strongest risk factor for CA-CDI followed by renal failure 23 
and haematological cancers. In patients with the described comorbidities, early identification 24 
and prompt treatment of CA-CDI may reduce mortality rates. The associations found 25 
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between CA-CDI and comorbidities may be confounded by medication exposure given that 1 
polypharmacy is common among patients with multiple comorbidities. Furthermore, the 2 
heterogeneous definition of CA-CDI across the studies (i.e. not hospitalized the year prior to 3 
the index date versus not hospitalized 6 weeks prior to the index date) may also be a source of 4 
misclassification between CA- and HA-CDI, considering that patients with multiple 5 
comorbidities are more likely to be admitted to hospitals.  6 
The sensitivity analyses suggested that risk of CA-CDI with exposure to antimicrobial 7 
and PPI differed between Europe and America. The observed difference might be due to the 8 
dissimilar prescription of antimicrobials
38
 and/or the presence of different strains of C. 9 
difficile in Europe and America.
39
 Similarly, the risk of CA-CDI with exposure to 10 
antimicrobials and PPI varied among the life stages. These findings were consistent with 11 
Sandora et al.
40 who reported a negative correlation between age and CA-CDI among 12 
paediatric populations and with Lessa et al.
41
 who reported a higher incidence of CDI among 13 
patients at both extremes of life (1-4 years of age and above 65 years of age). In the past two 14 
decades, a 12-fold increased incidence of CA-CDI among the paediatric population
42
 and 15 
numerous outbreaks in long-term-care facilities
43
 have been reported, indicating that infants, 16 
toddlers and older adults should be considered at high risk of CA-CDI. 17 
Although a comprehensive systematic search for studies was carried out, publication 18 
bias could have resulted in more positive associations being published such as those between 19 
CA-CDI and exposure to cephalosporins, fluoroquinolones, macrolides, and penicillins and 20 
the presence of congestive heart disease and GERD. The actual risks attributable to these risk 21 
factors could be less than what we have reported. Nevertheless, heterogeneity across studies 22 
could also result in effect size asymmetry and this represents an alternative explanation to 23 
selective publication of positive results.  24 
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 Recent meta-analyses have investigated the risk of CDI associated with exposure to 1 
antimicrobials
3,10,11
 and gastric acid suppressant drugs
3-5,13
 using the widely adopted RE 2 
model.
17
 However, it is known that the coverage probability of the RE CI can be substantially 3 
below the nominal level of 95 percent and thus does not adequately reflect the statistical error 4 
especially when there are few included studies.
12,23,44
 By underestimating the statistical error, 5 
the RE model produces tight CIs which potentially causes overconfident results prone to type 6 
1 error. Moreover, the assumption of normally distributed random effects is not easily 7 
verified.
44
 The use of a moment-based common variance
17
 within this model is in the 8 
redistribution of the weights from larger to smaller studies.
19
 The QE and IVhet models have 9 
both been created to do away with the problems that affect the RE model and both have 10 
coverage of the CI at or above the nominal level.
23
 As an example, with the clindamycin 11 
pooled estimates, the IVhet model distributed the weight (83.5%) toward the biggest study 12 
(Lowe et al.
33
 ; n=13,692). The QE model took into account the extra information regarding 13 
the quality of the studies and penalized the biggest study by reducing the assigned weight 14 
(from 83.5% to 69.0%) because it had the lowest quality score; whereas the RE model 15 
redistributed the weights by equalizing weights (by transferring from big to small studies) 16 
and thus, it gave a similar weight percentage to the biggest study (Lowe et al.
33
 ; n=13,692; 17 
weight 25.85%) and the smallest study (Vesteinsdottir et al.
45
 ; n=333; weight 23.98%). 18 
Moreover, the RE model produced a tighter CI (with a statistically significant result) but its 19 
coverage may have been under the nominal level and thus may not capture the true value of 20 
the effect (Appendix 3.3). 21 
 Several limitations of the present meta-analysis were noted. Kuntz et al.
9
 and 22 
Marwick et al.
32
 reported a positive relationship between time exposed to antimicrobials and 23 
CA-CDI. However, the small number of studies precluded a subgroup analysis by time of 24 
exposure to antimicrobials. All studies included in this meta-analysis were conducted in 25 
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Northern Hemisphere countries. A recent study has described a different seasonal pattern of 1 
CDI in Australia which remains largely unexplained.
46
 The epidemiological patterns of C. 2 
difficile transmission and infection may differ between hemispheres and thus generalizability 3 
of the findings to southern hemisphere countries is limited.  4 
 In conclusion, while antimicrobial use remains the dominant risk factor for CA-CDI, 5 
corticosteroid use should also be considered as an important risk factor. Given these are 6 
commonly prescribed medications in the community, the attributable risk of CDI due to 7 
exposure may be high and thus further research is warranted. In addition, patients with IBD, 8 
renal failure and haematological cancer are at higher risk of CA-CDI, making them 9 
appropriate populations for interventional studies of screening for C. difficile.   10 
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TABLES AND FIGURES 
Table 1.- Characteristics of the studies included in the meta-analysis. 
Author, 
publication 
year  
Data source Study period Study design Study 
population 
Age, years 
case/control 
mean (SD) 
years 
Male, % 
case/control 
 
Community-
acquired 
definition 
Case 
definition 
Control 
definition 
Matching Exposure to 
medication 
or presence 
of 
comorbidity, 
days prior 
index date 
N 
case/control 
Dial et al. 
200526 
& 
Delaney et al. 
200727 
GPRD, UK 1 Jan 1994 - 
31 Dec 2004 
Case-control ≥2 years 
registered in 
a general 
practice in 
the UK and 
≥18 years old 
71.0(16) / 
70.8(16) 
35 / 42 Not 
hospitalized 
the year prior 
to the index 
date 
Clinical 
diagnosis or 
positive toxin 
test results 
for CDI 
 
No clinical 
diagnosis nor 
positive toxin 
test result for 
CDI 
Practice 
location, age 
(±2 years) 
Gastric acid 
suppressant, 
antimicrobial
s, NSAID, 
aspirin, 90 
 
Comorbidity, 
720 
1233 / 12330 
Dial et al. 
200628 
GPRD, UK 1 Jan 1994 - 
31 Dec 2004 
Case-control Registered in 
the GPRD 
without 
clinical 
diagnosis or 
positive toxin 
65.0 (19.6) / 
64.9 (19.5) 
36.6 / 41.5 Not 
hospitalized 
the year prior 
to the index 
date 
Prescription 
of oral 
vancomycin 
therapy 
No 
prescription 
for oral 
vancomycin 
 
Practice 
location, age 
(±2 years) 
Gastric acid 
suppressant, 
antimicrobial
s, 90 
 
Comorbidity, 
317 / 3167 
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test results 
for CDI 30 
days to 1 
year prior the 
index date 
720 
Dial et al. 
200847 
Régie de 
l'assurance 
maladie du 
Québec and 
the MED-
ECHO,  
Canada 
1996 - 2004 Nested case-
control 
Hospitalized 
during the 
study period, 
≥65 years old 
and have not 
received 
metronidazol
e or oral 
vancomycin 
90 days prior 
the index 
date 
79.8 (6.8) / 
77.5 (6.3)  
33.7 / 40.9 Not admitted 
to any type 
of institution 
in the 90-day 
period before 
the index 
date 
First hospital 
admission 
with primary 
diagnosis of 
CDI (ICD-9 
code 008.45)  
No primary 
diagnosis of 
CDI during 
the first 
hospital 
admission 
Unmatched 
 
Index date 
and date of 
first hospital 
admission 
Antimicrobia
ls, 45 
 
Comorbidity, 
720 
836 / 8360 
Kuntz et al. 
20119 
The 
University of 
Iowa 
Wellmark 
Data 
Repository, 
USA 
1 Jan 2004 - 
31 Dec 2007 
Nested case-
control 
Patients with 
at least 1 
year of health 
and 
pharmacy 
insurance  
NR / NR 39.47 / 48.36 No history of 
long-term 
care facility 6 
months or 
hospitalized 
12 weeks 
before the 
Primary or 
secondary 
diagnosis of 
CDI (ICD-9 
code 008.45) 
No diagnosis 
of CDI on or 
before the 
index date 
Unmatched 
 
Index date 
Gastric acid 
suppressant, 
antimicrobial
s, 180 
 
Comorbidity, 
304 / 3040 
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index date 
Kutty et al. 
201031 † 
VA infection 
control 
database and 
Surveillance 
database of 
the Duke 
University 
Hospital 
network, 
USA 
Jan 2005 - 
Dec 2005 
Case-control ≥18 years old VA: 62 (38-
85) / 64 (38-
86) * 
 
Durham 
County: 61 
(20-101) / 55 
(22-87) * 
VA: 88 / 96 
 
Durham 
County: 42 / 
29 
No history of 
healthcare 
exposure 
within 8 
weeks of the 
index date 
Nonformed 
stool 
specimen 
with positive 
toxin test 
results for 
CDI 
Outpatients 
with no 
clinical 
diagnosis of 
diarrhea or 
positive toxin 
test results 
for CDI 
Unmatched Gastric acid 
suppressant, 
antimicrobial
s, NSAID, 90 
 
Comorbidity, 
NR 
VA: 36 / 108 
 
Durham 
County: 73 / 
48 
Lowe et al. 
200633 
Ontario Drug 
Benefit 
Program, 
Canadian 
Institute for 
Health 
Information 
Discharge 
Abstract 
Database, 
The Ontario 
Health 
Insurance 
1 Apr 2002 - 
31 Mar 2005 
Nested case-
control 
≥66 years old 
exposed to 
antimicrobial
s   
78.7 (7.2) / 
78.0 (6.8) 
59.8 / 60.5 Not 
hospitalized 
during the 
90-day 
period prior 
to the index 
date nor 
patients from 
long-term 
care or 
nursing 
homes 
Hospitalized 
with 
diagnosis of 
CDI (ICD-10 
code A04.7) 
Outpatient Index date, 
sex, age (±1 
years), 
antimicrobial
s prescribed 
Gastric acid 
suppressant, 
90 
 
Antimicrobia
ls, 60 
 
Comorbidity, 
180 - 720 
 
1389 / 12303 
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 5 
 6 
 7 
 8 
 9 
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12 
13 
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17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
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45 
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Plan 
Database and 
The Ontario 
Registered 
Persons 
Database, 
Canada 
Marwick et al. 
201332 
The Health 
Information 
Center at the 
University of 
Dundee, 
Scotland 
1 Nov 2008 - 
31 Oct 2009 
Nested case-
control 
≥65 year old  81 (8.9) / 81 
(8.9) 
27.4 / 27.4 Not 
hospitalized 
during the 
120-day 
period prior 
to the index 
Diarrhea and 
a positive 
toxin test 
results for 
CDI or 
positive C. 
difficile 
culture and 
pseudomemb
ranous colitis 
NR Sex, age (±1 
years), 
Gastric acid 
suppressant, 
antimicrobial
s, 180 
 
Comorbidity, 
360 
62 / 620 
Naggie et al. 
201148 
Duke 
University 
Medical 
Center, 
Durham 
Regional 
Hospital, 
1 Oct 2006 - 
31 Nov 2007 
Case-control ≥18 years old 64 (50-73) / 
63 (52-74) * 
44 / 45 Symptom 
onset in the 
community 
or within 72 
hours of 
admission to 
a healthcare 
Diarrhea and 
a positive 
toxin test 
results for 
CDI 
Outpatient 
with no 
diagnosis of 
CDI 
Unmatched 
 
Geographic 
location 
Gastric acid 
suppressant, 
antimicrobial
s, NSAID, 
aspirin, 90 
 
Comorbidity, 
66 / 114 
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Durham VA 
Medical 
Center, 
Salisbury 
VAMC and 
Asheville 
VAMC, USA 
facility. 
Not 
hospitalized 
during the 
12-week 
period prior 
to the index 
720 
Soes et al. 
201329,30 ‡ 
NR, 
Denmark 
24 Aug 2009 
- 28 Feb 
2011 
Nested case-
control 
Patients who 
had fecal 
sample 
submitted by 
their GP for 
microbiologi
cal testing 
due to 
diarrhea or 
other 
gastrointestin
al symptoms 
<2 years: 
0.95 (0.30-
1.98) / 1.06 
(0.25-1.98) 
 
≥2 years: 50 
(2-94) / 50 
(2-90) * 
 
<2 years: 53 / 
55 
 
≥2 years: 25 / 
28 
Not 
hospitalized 
during the 
12-week 
period prior 
to the index 
or onset of 
symptoms 
within 48 
hours of 
admission 
Positive C. 
difficile 
culture 
Negative C. 
difficile 
culture 
Laboratory 
location, sex, 
age (±2 years 
if ≥5years; 
±5 months if 
≥6months 
and <4years; 
±6 weeks if 
<6months) 
Antimicrobia
ls, 56 
 
Gastric acid 
suppressant, 
NSAID, 
aspirin, 120 
 
Comorbidity, 
120 
 
<2 years: 121 
/ 213 
 
≥2 years: 138 
/ 242 
 
 
Suissa et al. 
201249 
GPRD, UK 1 Jan 1994 - 
31 Dec 2005 
Case-control ≥2 years 
registered in 
a general 
practice in 
the UK and 
NR / NR NR / NR Not 
hospitalized 
the year prior 
to the index 
date 
First positive 
toxin test 
results for 
CDI or first 
prescription 
No clinical 
diagnosis, 
positive toxin 
test result for 
CDI or 
Practice 
location, age 
(±2 years) 
Gastric acid 
suppressant, 
antimicrobial
s, NSAID, 
aspirin, 90 
929 / 10242 
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≥18 years old of oral 
vancomycin 
 
prescription 
of oral 
vancomycin 
 
Comorbidity, 
720 
Vesteinsdottir 
et al. 201245 
The National 
University 
Hospital of 
Iceland, 
Iceland 
1 Jul 2010 - 
30 Jun 2011 
Case-control ≥18 years old 65 (56-80) / 
65 (55-80) * 
42.3 / 42.3 Not 
hospitalized 
during the 6-
week period 
prior to the 
index or 
lived in a 
nursing 
facility and if 
hospitalized, 
diagnosed 
with CDI 
within the 72 
hours of 
admission 
Positive 
toxin test 
results for 
CDI 
Negative 
toxin test 
results for 
CDI 
Sex, age (±5 
years), 
Gastric acid 
suppressant, 
antimicrobial
s,  42 
 
Comorbidity, 
84 
111 / 222 
Wilcox et al. 
200850 
Cornwall and 
Leeds, UK 
Jan 1999 - 
Dec 1999 
Case-control Patients who 
had fecal 
sample 
submitted by 
their GP for 
microbiologi
78 (4-100) / 
NR * 
44 / NR Patients that 
attended the 
GP 
Diarrhea and 
a positive 
toxin test 
results for 
CDI 
Negative 
toxin test 
results for 
CDI 
Sex, age 
categories 
Antimicrobia
ls,  180 
 
Comorbidity, 
NR 
 
40 / 112 
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cal testing 
GPRD: General Practice Research Database, MED-ECHO: Provincial hospital discharge summary, VA: Veterans Affairs, ICD: International Classification of Disease, GP: General practitioner, 
NR: Not reported, Index date: The date when the cases were identified 
* Age, median (range) years 
† Presented in 2 groups: Patients from the VA and Durham County 
‡ Presented in 2 groups: Patients aged <2 years and ≥2 years 
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Table 2.- Modified Newcastle-Ottawa quality assessment scale for case-control studies included in the meta-analysis. 
Author, publication year Definition 
of cases 
Case selection 
for  community-
acquired 
infection 
Definition 
of controls 
Control 
selection  
Analysis 
adjusted for 
confounders 
Ascertainment 
of exposure 
Method of 
ascertainment 
of exposure for 
cases and 
controls 
Total 
score 
(points) 
Qi 
(total 
score/13) 
Dial et al. 200526 1 1 1 2 2 3 1 11 0.85 
Dial et al. 200628 0 1 0 2 2 3 1 9 0.69 
Dial et al. 200847 1 1 1 1 3 3 1 11 0.85 
Kuntz et al. 20119 1 2 1 2 3 3 1 13 1.00 
Kutty et al. 201031 2 2 2 1 1 3 0 11 0.85 
Lowe et al. 200633 1 2 0 1 2 3 1 10 0.77 
Marwick et al. 201332 2 1 0 2 1 3 1 10 0.77 
Naggie et al. 201148 2 2 2 1 2 1 1 11 0.85 
Soes et al. 201329 3 2 3 2 0 1 1 12 0.92 
Suissa et al. 201249 0 1 0 2 2 3 1 9 0.69 
Vesteinsdottir et al. 201245 2 2 2 2 0 1 1 10 0.77 
Wilcox et al. 200850 2 0 2 2 0 2 1 9 0.69 
(i) Definition of cases. Method used for C. difficile diagnosis: Stool culture (3 points), Toxin detection (2 points), Clinical diagnosis or ICD code (1 point), Other or no description 
(0 points) 
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(ii) Case selection for community-acquired infection: Patient not previously hospitalized and not a resident of a nursing home (2 points),  Patient not previously hospitalized or not 
a resident of a nursing home (1 point), No description (0 points) 
(iii) Definition of controls. Method used for exclusion (non infection) of C. difficile: Stool culture (3 points), Toxin detection (2 points), Clinical diagnosis or ICD code (1 point), 
Other or no description (0 points) 
(iv) Control selection: Community (2 points), Community and hospital (1 point), No description (0 points) 
(v) Analysis adjusted for exposures other than the primary exposure of interest (sex, age, antimicrobial exposure, gastric acid-suppressive medication exposure or presence of 
comorbidities). Adjusted for: 5 factors (3 points), 3-4 factors (2 points), 1-2 factors (1 point), non adjusted (0 points) 
(vi) Ascertainment of exposure: Objective methods i.e. charts or medical records (3 points), Reported by the general practitioner (2 points), Self-reported (1 point), No description 
(0 points)  
(vii) Method of ascertainment of exposure for cases and controls: Same (1 point), Different (0 points) 
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Table 3.- Pooled effect size using the IVhet model, QE model and the RE model   
Exposure IVhet model  
OR (95% CI) 
QE model  
OR (95% CI) 
RE model  
OR (95% CI) 
Heterogeneity 
I2 index % 
Antimicrobials 6.18 (3.80 - 10.04) 6.11 (3.92 - 9.55) 5.92 (4.21 - 8.32) 87.90 
 Cephalosporins 1.80 (0.38 - 8.46) 2.09 (0.55 - 7.98) 3.29 (1.20 - 9.05) 98.39 
 Clindamycin 2.32 (0.14 - 37.99) 3.21 (0.30 - 34.55) 8.35 (1.54 - 45.20) 97.73 
 Fluoroquinolones 1.55 (0.32 - 7.57) 1.90 (0.51 - 7.05) 3.59 (1.60 - 8.06) 96.97 
 Macrolides 1.26 (0.49 - 3.24) 1.45 (0.64 - 3.28) 2.15 (1.11 - 4.17) 93.38 
 Penicillins 1.31 (0.57 - 3.01) 1.54 (0.75 - 3.16)      2.40 (1.40 - 4.11) 93.50 
 Tetracyclines 0.98 (0.68 - 1.41) 0.98 (0.67 - 1.41) 0.98 (0.68 - 1.41) * 0 
 TMP-SMX 1.26 (0.75 - 2.12) 1.30 (0.80 - 2.10) 1.37 (0.87 - 2.15)  77.37 
Gastric acid suppressant 1.58 (0.90 - 2.75) 1.58 (0.95 - 2.63) 1.58 (1.06 - 2.34) 68.89 
 H2RA  1.24 (0.76 - 2.01) 1.24 (0.78 - 1.96) 1.37 (0.96 - 1.96) 73.95 
 PPI 1.61 (0.90 - 2.88) 1.63 (0.95 - 2.80) 1.68 (1.11 - 2.55) 92.23 
Other medication     
 Aspirin 0.97 (0.87 - 1.08) 0.96 (0.85 - 1.08) 0.97 (0.87 - 1.08) * 0 
 NSAIDs 1.14 (0.67 - 1.93) 1.04 (0.63 - 1.71) 0.83 (0.56 - 1.23) 90.42 
 Corticosteroids 1.81 (1.15 - 2.84) 1.84 (1.22 - 2.77) 1.65 (1.14 - 2.38) 34.79 
Comorbidities     
 Congestive heart disease 0.95 (0.45 - 2.01) 0.98 (0.46 - 2.06) 1.40 (0.77 - 2.54) 68.70 
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 COPD 1.04 (0.93 - 1.16) 1.04 (0.93 - 1.16) 1.04 (0.93 - 1.16) * 0 
 Diabetes mellitus 1.15 (1.05 - 1.27) 1.14 (1.04 - 1.26) 1.15 (1.05 - 1.27) * 0 
 Diverticular disease  1.15 (0.98 - 1.36) 1.15 (0.98 - 1.35) 1.15 (0.98 - 1.36) * 0 
 GERD 1.02 (0.74 - 1.43) 1.03 (0.74 - 1.43) 1.07 (0.80 - 1.44) 45.53 
 IBD  3.72 (1.52 - 9.12) 4.11 (1.78 - 9.49) 5.19 (2.49 - 10.83) 89.39 
 Leukemia or Lymphoma 1.75 (1.02 - 3.03) 1.74 (1.01 - 3.01) 1.88 (1.09 - 3.21) 38.95 
 Peptic ulcer 0.97 (0.60 - 1.57) 0.96 (0.59 - 1.56) 0.94 (0.58 - 1.51) 14.72 
 Renal failure 2.64 (1.23 - 5.68) 2.59 (1.20 - 5.59) 3.02 (1.66 - 5.48) 85.96 
 Solid cancer 1.34 (0.83 - 2.17)  1.35 (0.84 - 2.17) 1.51 (1.01 - 2.27) 81.64 
* No heterogeneity, pooled estimated report using the inverse variance model. 
IVhet: Inverse variance heterogeneity, QE: Quality effects, RE: Random effects, OR: odds ratio, TMP-SMX: Trimethorpim/sulfamethoxazole, H2RA: histamine-2-
receptor antagonists, PPI: Proton pump inhibitors, NSAIDs: Non-steroidal anti-inflammatory drugs, COPD: Chronic obstructive pulmonary disease, GERD: Gastro-
esophageal reflux disease, IBD: Inflammatory bowel disease 
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Figure 1.- PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analysis) 
flowchart of the literature search conducted on the 1
st
 March 2014 for the meta-analysis 
 
 
  
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
28 
 
REFERENCES 
1. McGlone SM, Bailey RR, Zimmer SM, et al. The economic burden of Clostridium 
difficile. Clin Microbiol Infec. 2012;18:282-289. 
2. Freeman J, Bauer MP, Baines SD, et al. The Changing Epidemiology of Clostridium 
difficile Infections. Clin Microbiol Rev. 2010;23:529-549. 
3. Kwok CS, Arthur AK, Anibueze CI, Singh S, Cavallazzi R, Loke YK. Risk of 
Clostridium difficile infection with acid suppressing drugs and antibiotics: meta-
analysis. Am J Gastroenterol. 2012;107:1011-1019. 
4. Janarthanan S, Ditah I, Adler DG, Ehrinpreis MN. Clostridium difficile-associated 
diarrhea and proton pump inhibitor therapy: a meta-analysis. Am J Gastroenterol. 
2012;107:1001-1010. 
5. Tleyjeh IM, Abdulhak AB, Riaz M, et al. The association between histamine 2 
receptor antagonist use and Clostridium difficile infection: a systematic review and 
meta-analysis. PloS One. 2013;8:e56498. 
6. Goodhand JR, Alazawi W, Rampton D. Systematic review: Clostridium difficile and 
inflammatory bowel disease. Aliment Pharmacol Ther. 2011;33:428-441. 
7. Ahmed N, Kuo YH, Kuo YL, Davis JM. Risk factors for mortality in patients 
admitted with the primary diagnosis of clostridium difficile colitis: A retrospective 
cohort study using nationwide inpatient sample (NIS) database. Surg Infect. 
2011;12:S73-S74. 
8. Bajaj JS, O'Leary JG, Reddy KR, et al. Second infections independently increase 
mortality in hospitalized patients with cirrhosis: the North American consortium for 
the study of end-stage liver disease (NACSELD) experience. Hepatology. 
2012;56:2328-2335. 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
29 
 
9. Kuntz JL, Chrischilles EA, Pendergast JF, Herwaldt LA, Polgreen PM. Incidence of 
and risk factors for community-associated Clostridium difficile infection: a nested 
case-control study. BMC Infect Dis. 2011;11:194. 
10. Deshpande A, Pasupuleti P, Thota P, et al. Community-associated clostridium 
difficile infection antibiotics: A meta-analysis. J Antimicrob Chemoth. 2013;68:1951-
1961. 
11. Brown KA, Khanafer N, Daneman N, Fisman DN. Meta-analysis of antibiotics and 
the risk of community-associated Clostridium difficile infection. Antimicrob Agents 
Ch. 2013;57:2326-2332. 
12. Noma H. Confidence intervals for a random-effects meta-analysis based on Bartlett-
type corrections. Stat Med. 2011;30:3304-3312. 
13. Tleyjeh IM, Bin Abdulhak AA, Riaz M, et al. Association between proton pump 
inhibitor therapy and clostridium difficile infection: a contemporary systematic 
review and meta-analysis. PloS One. 2012;7:e50836. 
14. Heidelbaugh JJ, Goldberg KL, Inadomi JM. Adverse risks associated with proton 
pump inhibitors: A systematic review. J Gastroen Hepatol. 2009;5:725-734. 
15. Shukla S, Shukla A, Guha S, Mehboob S. Use of proton pump inhibitors and risk of 
clostridium difficile-associated diarrhea: A meta-analysis. Gastroenterology. 
2010;138:S209. 
16. Waffenschmidt S, Janzen T, Hausner E, Kaiser T. Simple search techniques in 
PubMed are potentially suitable for evaluating the completeness of systematic 
reviews. J Clin Epidemiol. 2013;66:660-665. 
17. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 
1986;7:177-188. 
18. Senn S. Trying to be precise about vagueness. Stat Med. 2007;26:1417-1430. 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
30 
 
19. Al Khalaf MM, Thalib L, Doi SA. Combining heterogenous studies using the 
random-effects model is a mistake and leads to inconclusive meta-analyses. J Clin 
Epidemiol. 2011;64:119-123. 
20. Poole C, Greenland S. Random-effects meta-analyses are not always conservative. 
Am J Epidemiol. 1999;150:469-475. 
21. Doi SA, Thalib L. A quality-effects model for meta-analysis. Epidemiology. 
2008;19:94-100. 
22. Doi SA, Barendregt JJ, Mozurkewich EL. Meta-analysis of heterogeneous clinical 
trials: an empirical example. Contemp Clin Trials. 2011;32:288-298. 
23. Barendregt JJ, Doi SA. An easy fix for the RE model: The IVhet model. In: MetaXL 
User Guide - Version 20. Brisbane, Australia, 2014:25-29. Available at: 
http://www.epigear.com/index_files/MetaXL%20User%20Guide.pdf. Accessed 
August 1, 2014 
24. Onitilo AA, Doi SAR, Barendregt JJ. Meta-analysis II: Interpretation and use of 
outputs. In: Doi SAR, Williams GM, eds. Methods of clinical epidemiology. Berlin: 
Springer Berlin Heidelberg; 2013:253-266. 
25. Sterne JAC, Sutton AJ, Ioannidis JPA, et al. Recommendations for examining and 
interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. 
Brit Med J. 2011;343:d4002. 
26. Dial S, Delaney JA, Barkun AN, Suissa S. Use of gastric acid-suppressive agents and 
the risk of community-acquired Clostridium difficile-associated disease. JAMA. 
2005;294:2989-2995. 
27. Delaney JA, Dial S, Barkun A, Suissa S. Antimicrobial drugs and community-
acquired Clostridium difficile-associated disease, UK. Emerg Infect Dis. 
2007;13:761-763. 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
31 
 
28. Dial S, Delaney JA, Schneider V, Suissa S. Proton pump inhibitor use and risk of 
community-acquired Clostridium difficile-associated disease defined by prescription 
for oral vancomycin therapy. Can Med Assoc J. 2006;175:745-748. 
29. Soes LM, Holt HM, Bottiger B, et al. Risk factors for Clostridium difficile infection 
in the community: a case-control study in patients in general practice, Denmark, 
2009-2011. Epidemiol Infect. 2013;27:1-12. 
30. Soes LM, Holt HM, Bottiger B, et al. The incidence and clinical symptomatology of 
Clostridium difficile infections in a community setting in a cohort of Danish patients 
attending general practice. Euro J Clin Microbiol. 2014;33:957-967. 
31. Kutty PK, Woods CW, Sena AC, et al. Risk factors for and estimated incidence of 
community-associated Clostridium difficile infection, North Carolina, USA. Emerg 
Infect Dis. 2010;16:197-204. 
32. Marwick CA, Yu N, Lockhart MC, et al. Community-associated Clostridium difficile 
infection among older people in Tayside, Scotland, is associated with antibiotic 
exposure and care home residence: cohort study with nested case-control. J 
Antimicrob Chemoth. 2013;68:2927-2933. 
33. Lowe DO, Mamdani MM, Kopp A, Low DE, Juurlink DN. Proton pump inhibitors 
and hospitalization for Clostridium difficile-associated disease: a population-based 
study. Clin Infect Dis. 2006;43:1272-1276. 
34. Durand C, Willett KC, Desilets AR. Proton pump inhibitor use in hospitalized 
patients: Is overutilization becoming a problem? Clin Med Insights Gastroenterol. 
2012;5:65-76. 
35. Johnson S, Gerding DN. Clostridium difficile-Associated Diarrhea. Clin Infect Dis. 
1998;26:1027-1034. 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
32 
 
36. Jump RL, Pultz MJ, Donskey CJ. Vegetative Clostridium difficile survives in room 
air on moist surfaces and in gastric contents with reduced acidity: a potential 
mechanism to explain the association between proton pump inhibitors and C. difficile-
associated diarrhea? Antimicrob Agents Ch. 2007;51:2883-2887. 
37. Hernández-Díaz S, Rodríguez LAG. Steroids and Risk of Upper Gastrointestinal 
Complications. Am J Epidemiol. 2001;153:1089-1093. 
38. Patrick DM, Marra F, Hutchinson J, Monnet DL, Ng H, Bowie WR. Per capita 
antibiotic consumption: how does a North American jurisdiction compare with 
Europe? Clin Infect Dis. 2004;39:11-17. 
39. Cheknis AK, Sambol SP, Davidson DM, et al. Distribution of Clostridium difficile 
strains from a North American, European and Australian trial of treatment for C. 
difficile infections: 2005-2007. Anaerobe. 2009;15:230-233. 
40. Sandora TJ, Flaherty K, Helsing L, et al. Epidemiology and risk factors for 
clostridium difficile infection in children. Am J Infect Control. 2009;37:E61. 
41. Lessa FC, Gould CV, McDonald LC. Current Status of Clostridium difficile Infection 
Epidemiology. Clin Infect Dis. 2012;55:S65-S70. 
42. Khanna S, Baddour LM, Huskins WC, et al. The epidemiology of Clostridium 
difficile infection in children: a population-based study. Clin Infect Dis. 
2013;56:1401-1406. 
43. Simor AE, Bradley SF, Strausbaugh LJ, Crossley K, Nicolle LE. Clostridium difficile 
in long-term-care facilities for the elderly. Infect Control Hosp Ep. 2002;23:696-703. 
44. Brockwell SE, Gordon IR. A comparison of statistical methods for meta-analysis. Stat 
Med. 2001;20:825-840. 
45. Vesteinsdottir I, Gudlaugsdottir S, Einarsdottir R, Kalaitzakis E, Sigurdardottir O, 
Bjornsson ES. Risk factors for Clostridium difficile toxin-positive diarrhea: a 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
33 
 
population-based prospective case-control study. Eur J Clin Microbiol. 2012;31:2601-
2610. 
46. Furuya-Kanamori L, Robson J, Soares Magalhãesa RJ, et al. A population-based 
spatio-temporal analysis of Clostridium difficile infection in Queenland, Australia 
over a 10-year period J Infect (in press). 
47. Dial S, Kezouh A, Dascal A, Barkun A, Suissa S. Patterns of antibiotic use and risk of 
hospital admission because of Clostridium difficile infection. Can Med Assoc J. 
2008;179:767-772. 
48. Naggie S, Miller BA, Zuzak KB, et al. A case-control study of community-associated 
Clostridium difficile infection: no role for proton pump inhibitors. Am J Med. 
2011;124:276.e271-277. 
49. Suissa D, Delaney JAC, Dial S, Brassard P. Non-steroidal anti-inflammatory drugs 
and the risk of Clostridium difficile-associated disease. Brit J Clin Pharmaco. 
2012;74:370-375. 
50. Wilcox MH, Mooney L, Bendall R, Settle CD, Fawley WN. A case-control study of 
community-associated Clostridium difficile infection. J Antimicrob Chemoth. 
2008;62:388-396. 
 
 
 
 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
Figure 1
35 
 
APPENDICES 
Appendix 1.- Search strategies 
PubMed 
(((("Community-Acquired Infections"[MeSH Terms]) OR (Community OR Communities OR 
Residential OR Neighborhood OR Neighborhoods OR Neighbourhood OR 
Neighbourhoods)))  
AND  
("Clostridium"[Mesh] OR Clostridium))  
AND 
Difficile 
 
Embase 
('communicable disease'/exp OR community OR communities OR residential OR 
neighborhood OR neighborhoods OR neighbourhood OR neighbourhoods)  
AND 
'clostridium'/exp OR clostridium  
AND  
Difficile  
 
CINAHL 
(MH "Community-Acquired Infections+")  OR Community OR Communities OR Residential 
OR Neighborhood OR Neighborhoods OR Neighbourhood OR Neighbourhoods  
AND 
(MH "Clostridium+") OR Clostridium 
AND 
Appendices
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Difficile 
 
Cochrane CENTRAL 
(((("Community-Acquired Infections"[MeSH Terms]) OR (Community OR Communities OR 
Residential OR Neighborhood OR Neighborhoods OR Neighbourhood OR 
Neighbourhoods)))  
AND 
("Clostridium"[Mesh] OR Clostridium))  
AND  
Difficile 
 
Scopus 
(TITLE-ABS-KEY(community OR communities OR residential OR neighborhood OR 
neighborhoods OR neighbourhood OR neighbourhoods)  
AND  
TITLE-ABS-KEY(clostridium)  
AND  
TITLE-ABS-KEY(difficile))  
 
 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
35 
 
Appendix 2.- Data extraction tool 
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Appendix 3.- Forest, Funnel and Doi plots 
  
 
 
3.1.- Antimicrobials  
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3.2.- Cephalosporins     
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3.3.- Clindamycin   
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3.4.- Fluoroquinolones    
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3.5.- Macrolides      
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3.6.- Penicillins        
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3.7.- Tetracyclines  
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3.8.- Trimethoprim/sulfamethoxazole 
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3.9.- Gastric acid suppressant 
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3.10.- Histamine-2 receptor antagonists    
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3.11.- Proton pump inhibitor  
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3.12.- Aspirin 
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3.13.- Non-steroidal anti-inflammatory drugs 
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3.14.- Corticosteroids     
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3.15.- Congestive heart disease 
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3.16.- Chronic obstructive pulmonary disease 
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3.17.- Diabetes mellitus 
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3.18.- Diverticular disease 
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3.19.- Gastroesophageal reflux disease 
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3.20.- Inflammatory bowel disease 
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3.21.- Leukemia or Lymphoma     
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3.22.- Peptic ulcer     
 
  
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
58 
 
  
  
 
3.23.- Renal failure 
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3.24.- Solid cancer 
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Appendix 4.- Sensitivity analysis 
  
  
4.1.- Antimicrobials by location 
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4.2.- Proton pump inhibitors by location 
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4.3.- Antimicrobials by life stage 
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4.4.- Proton pump inhibitors by life stage 
 
 
 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
